SCHEMBL404782

SCHEMBL404782

O=C(CCC(=O)OC(=O)c1ccccc1C(=O)O)OC(=O)c1ccccc1C(=O)O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.56
ALOX15 P16050 1/20 0.56
AKR1C3 P42330 1/20 0.45
TSHR P16473 1/20 0.44
KDM4E B2RXH2 3/20 0.44
KMT2A Q03164 3/20 0.44
MEN1 O00255 1/20 0.44
RECQL P46063 1/20 0.44
HPGD P15428 2/20 0.43
CA12 O43570 1/20 0.43
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43
HMGB1 P09429 1/20 0.43
CA4 P22748 1/20 0.43
CA6 P23280 1/20 0.43
CA7 P43166 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
CA9 Q16790 1/20 0.43
NAPRT Q6XQN6 1/20 0.43
CA14 Q9ULX7 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27583154 0.94 ALDH1A1 (0.50) ALDH1A1ALOX15AKR1C3TSHRKDM4E
SCHEMBL5523432 0.92 ALDH1A1 (0.52) ALDH1A1ALOX15AKR1C3TSHRKDM4E
SCHEMBL29090806 0.91 ALDH1A1 (0.47) ALDH1A1ALOX15TSHRKDM4EKMT2A
SCHEMBL27547208 0.91 ALDH1A1 (0.47) ALDH1A1ALOX15AKR1C3TSHRKDM4E
SCHEMBL9468429 0.91 ALDH1A1 (0.50) ALDH1A1ALOX15AKR1C3TSHRKDM4E
SCHEMBL28630802 0.89 ALDH1A1 (0.49) ALDH1A1ALOX15AKR1C3TSHRKDM4E
SCHEMBL27469326 0.89 KDM4E (0.50) ALDH1A1ALOX15TSHRKDM4EKMT2A
SCHEMBL28630572 0.89 ALDH1A1 (0.49) ALDH1A1ALOX15AKR1C3TSHRKDM4E
SCHEMBL125859 0.88 NR4A2 (0.45) ALDH1A1ALOX15TSHRHPGDSMN1; SMN2
Succinic Acid SCHEMBL22217135 0.88 NR4A2 (0.45) ALDH1A1ALOX15TSHRHPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 217 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024119044-A2 ADRULIPASE COMPOSITIONS First Wave BioPharma, Inc. (US) 2024-06-06 WO claimed
US-9149439-B2 Multi-particulate, modified-release composition SANDOZ AG (CH) 2015-10-06 US claimed
CN-103804906-A Improved PPA plastic SUZHOU HANXIN PLASTIC INDUSTRY CO LTD 2014-05-21 CN claimed
EP-2507203-A1 NEW PROCESS FOR THE PREPARATION OF TAPENTADOL AND INTERMEDIATES THEREOF Euticals S.P.A. (IT) 2012-10-10 EP claimed
US-8168228-B2 Oral micropellets containing an antibiotic having an inner coating of a cellulose polymer (not enteric)and an outer coating of an enteric coating polymer; particle size of 100 to 650 mu m.; lack of bitter taste; fast dissolution; increased antibiotic bioavailability compared pellets having a matrix SANDOZ AG (CH) 2012-05-01 US claimed
WO-2011067714-A1 NEW PROCESS FOR THE PREPARATION OF TAPENTADOL AND INTERMEDIATES THEREOF ARCHIMICA SRL (IT) 2011-06-09 WO claimed
US-20100215747-A1 NANOPARTICLES COMPRISING IONIZABLE, POORLY WATER SOLUBLE CELLULOSIC POLYMERS BEND RESEARCH, INC. 2010-08-26 US claimed
EP-2178518-A2 NANOPARTICLES COMPRISING IONIZABLE, POORLY WATER SOLUBLE CELLULOSIC POLYMERS Bend Research, Inc (US) 2010-04-28 EP claimed
WO-2009010842-A2 NANOPARTICLES COMPRISING IONIZABLE, POORLY WATER SOLUBLE CELLULOSIC POLYMERS PFIZER PRODUCTS INC. (US) 2009-01-22 WO claimed
EP-1680088-B1 Taste-masked formulation comprising clarithromycin SANDOZ AG (CH) 2008-12-03 EP claimed
US-20070048379-A1 Valproate tablet GUO MINTONG 2007-03-01 US claimed
CN-1893927-A Antibiotic composition SANDOZ AG (CH) 2007-01-10 CN claimed
WO-2006102446-A2 MULTI-PARTICULATE, MODIFIED-RELEASED COLONIC COMPOSITION SANDOZ AG (CH) 2006-09-28 WO claimed
US-20060210631-A1 Multi-particulate, modified-release composition SANDOZ AG (CH) 2006-09-21 US claimed
EP-1680088-A1 ANTIBIOTIC COMPOSITIONS Sandoz AG (CH) 2006-07-19 EP claimed
WO-2005077342-A1 ENTERICALLY COATED LANSOPRAZOLE MICROTABLETS SANDOZ AG (CH) 2005-08-25 WO claimed
US-20050181052-A1 Lansoprazole microtablets PATEL SATISHKUMAR A (US) 2005-08-18 US claimed
WO-2005039536-A1 ANTIBIOTIC COMPOSITIONS SANDOZ AG (CH) 2005-05-06 WO claimed
US-20050084540-A1 Oral micropellets containing an antibiotic having an inner coating of a cellulose polymer (not enteric)and an outer coating of an enteric coating polymer; particle size of 100 to 650 mu m.; lack of bitter taste; fast dissolution; increased antibiotic bioavailability compared pellets having a matrix SANDOZ INC. 2005-04-21 US claimed
US-20050084541-A1 Antibiotic compositions SANDOZ, AG (CH) 2005-04-21 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100215747-A1 NANOPARTICLES COMPRISING IONIZABLE, POORLY WATER SOLUBLE CELLULOSIC POLYMERS CEL, GYS1, TNNC1 ALDH1A1 3658/4885ALOX15 2345/4885AKR1C3 3743/4885
US-20070048379-A1 Valproate tablet CACNA1A, SUCLG2, CACNA1G ALDH1A1 1386/4885ALOX15 3316/4885AKR1C3 3027/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.